B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $68
B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $68
美林證券維持對ionis pharmaceuticals的買入評級，將目標股價上調至68美元。
B of A Securities analyst Jason Gerberry maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and raises the price target from $67 to $68.
B of A Securities分析師Jason Gerberry認爲Ionis Pharmaceuticals (NASDAQ:IONS)值得買入，並將目標股價從67美元升至68美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。